ALDOB K87 Lactylation Drives Mitochondrial Fission in Pulmonary Hypertension

Pulmonary hypertension (PH) is characterized by progressive pulmonary vascular remodeling, narrowing or occlusion of the pulmonary circulation, and eventual right-ventricular stress. Although vasodilator therapies can improve hemodynamics, they do not fully reverse the structural disease process. The reference study, “ALDOB K87 lactylation drives mitochondrial fission and metabolic reprogramming in pulmonary hypertension”, addresses this gap by examining how altered metabolism is coupled to mitochondrial behavior in pulmonary artery smooth muscle cells (PASMCs).

Study Background and Research Question

Pathological PASMC proliferation, migration, and phenotypic switching are central features of pulmonary vascular remodeling. In PH, these cells display a metabolic shift away from oxidative phosphorylation and toward aerobic glycolysis. This Warburg-like state can provide biosynthetic intermediates and energy for growth, but it also increases lactate production. Lactate is not only a metabolic end product; it can serve as a substrate for lysine lactylation, a post-translational modification affecting histone and nonhistone proteins.

The study asked whether nonhistone lactylation directly contributes to PH-associated vascular remodeling and, if so, which protein and downstream organelle pathway are involved. The investigators focused on aldolase B (ALDOB), a glycolytic enzyme, after identifying increased lactylation at lysine 87. Their central hypothesis was that ALDOB K87 lactylation could connect glycolytic rewiring to mitochondrial fragmentation and abnormal PASMC behavior.

Key Innovation from the Reference Study

The principal innovation is the proposed lactate–ALDOB–DRP1 axis. According to the reference study, hypoxia increases glycolytic flux and lactate accumulation, which is associated with enhanced ALDOB K87 lactylation. Rather than treating lactate as a passive biomarker of metabolic stress, the work places lactate-linked protein modification upstream of a defined mitochondrial remodeling pathway.

Mechanistically, lactylated ALDOB was reported to promote recruitment of dynamin-related protein 1 (DRP1) to mitochondria through sentrin/SUMO-specific peptidase 3 (SENP3)-mediated deSUMOylation of DRP1. DRP1 recruitment favors mitochondrial fission. In PASMCs, the resulting fragmentation was linked to increased proliferation, migration, and phenotypic switching. This provides a molecular explanation for how a glycolytic state may reinforce the cellular remodeling program in PH.

A second important feature is the identification of sirtuin 1 (SIRT1) as a delactylase for ALDOB. The study reports that SIRT1 is downregulated in PH, thereby reducing removal of the modification and allowing ALDOB lactylation to persist. This creates a feed-forward model: hypoxia promotes glycolysis and lactate production; lactate-associated ALDOB modification supports mitochondrial fission; and mitochondrial and metabolic changes further sustain the pathological cell state. The internal overview of ALDOB K87 lactylation summarizes this same mechanistic chain, while the reference paper provides the primary experimental basis.

Methods and Experimental Design Insights

Integrated discovery and validation

The investigators combined lactylomic profiling in hypoxic human PASMCs with validation in rodent PH models. This design is useful because it begins with an unbiased search for disease-associated lactylation events and then tests whether the candidate pathway is reproduced in an organismal disease context. The approach also links several levels of biology: protein modification, glycolytic flux, lactate accumulation, mitochondrial morphology, and PASMC phenotype.

At the cellular level, hypoxia was used to model a metabolic environment relevant to pulmonary vascular disease. The study then examined ALDOB lactylation, mitochondrial fission, DRP1 localization, and disease-associated cell behaviors. The animal experiments extended these observations by testing whether manipulating ALDOB lactylation altered PH progression in vivo.

Causal perturbation strategy

The causal argument did not rely solely on correlation. Genetic or pharmacological suppression of ALDOB lactylation was used to test whether the modification is required for the pathological phenotype. Conversely, lactylation-mimetic ALDOB mutants were used to determine whether persistent modification is sufficient to worsen mitochondrial and vascular abnormalities. The reported contrast between suppression and mimicry strengthens the interpretation that ALDOB lactylation is functionally important rather than merely a consequence of hypoxia.

The study also examined regulatory relationships involving SIRT1, ALDOB, SENP3, and DRP1. This is a particularly informative design choice because mitochondrial fission can be viewed as a downstream readout, whereas the SIRT1 and SENP3 experiments address how the modification and its consequences are controlled. For researchers planning related work, the model suggests that modification-specific assays should be paired with localization and functional measurements rather than used in isolation.

Protocol Parameters

• Discovery model: Use hypoxic human PASMCs to assess disease-associated lactylation changes, glycolytic activity, lactate accumulation, and mitochondrial morphology.
• Modification analysis: Pair global lactylomic profiling with site-directed validation of ALDOB K87 so that candidate-site discovery and mechanistic confirmation remain distinct steps.
• Mitochondrial readouts: Measure DRP1 recruitment and mitochondrial fragmentation together; either endpoint alone provides an incomplete view of the fission process.
• Causal controls: Include ALDOB-lactylation suppression and a lactylation-mimetic comparison, with appropriate expression and viability controls to distinguish pathway effects from nonspecific toxicity.
• Phenotypic endpoints: Evaluate PASMC proliferation, migration, and phenotypic switching alongside metabolic and mitochondrial measurements.
• In vivo confirmation: Validate the pathway in a rodent PH model before inferring relevance to whole-organism vascular remodeling; cellular findings alone should not be treated as evidence of therapeutic efficacy.

Core Findings and Why They Matter

1. ALDOB K87 is a disease-associated lactylation site

The lactylomic data identified increased ALDOB K87 lactylation in hypoxic PASMCs, and the modification was validated in rodent PH models, according to the reference study. This finding expands the role of lactylation in PH beyond preliminary descriptions of global modification changes. It also identifies a specific metabolic enzyme that may act as a signaling node.

2. Lactylation reinforces glycolytic remodeling

Hypoxia-induced ALDOB lactylation was associated with amplified glycolytic flux, lactate accumulation, and self-reinforcing lactylation. The implication is not simply that PH cells produce more lactate. Rather, the metabolic environment may help maintain a post-translational modification state that stabilizes the pathological phenotype. This provides a plausible biochemical explanation for the persistence of metabolic reprogramming in remodeled pulmonary vessels.

3. ALDOB modification promotes mitochondrial fission

The study links lactylated ALDOB to mitochondrial recruitment of DRP1 through SENP3-mediated DRP1 deSUMOylation. Increased fission was associated with PASMC proliferation, migration, and phenotypic switching. This result is significant because it joins two research areas that are often studied separately: glycolytic metabolism and mitochondrial dynamics. The proposed mechanism suggests that mitochondrial morphology is not merely a downstream marker of cellular stress but part of the machinery supporting vascular remodeling.

4. SIRT1 provides a regulatory counterbalance

SIRT1 was identified as an ALDOB delactylase, and its reduction in PH was reported to sustain ALDOB lactylation. This places SIRT1 in a regulatory position upstream of the mitochondrial phenotype. The finding may help explain why a pathological modification persists even when the initiating hypoxic stimulus is variable. It also offers a framework for testing whether restoration of delactylation capacity can interrupt the metabolic–mitochondrial feedback loop.

5. Intervention experiments support biological relevance

Suppression of ALDOB lactylation attenuated mitochondrial fission and PH progression in vivo, whereas lactylation-mimetic mutants aggravated disease-associated phenotypes. These results do not establish a clinical treatment, but they do support ALDOB lactylation as a candidate mechanistic target. The broader contribution is conceptual: post-translational control of a glycolytic enzyme can influence organelle dynamics and vascular cell behavior across experimental scales.

Comparison with Existing Internal Articles

The internal article “ALDOB K87 Lactylation Orchestrates Mitochondrial Fission in PH” presents the study primarily as a link between lactate metabolism, mitochondrial fragmentation, and PASMC proliferation. The reference paper supports that interpretation but adds greater methodological depth through integrated lactylomic discovery, SIRT1 regulation, SENP3-dependent DRP1 control, and in vivo perturbation.

A separate resource, “Optimizing Cell Proliferation Assays with Murine Recombinant PDGF-BB”, focuses on reproducible mitogenic assay design rather than the ALDOB mechanism. Its relevance is practical: a controlled growth-factor stimulus can be used to benchmark smooth muscle cell proliferation in a broader vascular research workflow. However, such an assay should be treated as complementary experimental context, not as evidence that the reference study tested PDGF-BB or established a direct connection between PDGF-BB signaling and ALDOB K87 lactylation.

Why this cross-domain matters, maturity, and limitations

The cross-domain connection is useful because vascular researchers often need both mechanistic disease models and controlled proliferation inputs. A defined mitogen can help establish assay performance, dynamic range, and cell-state responsiveness before investigators examine hypoxia, lactylation, mitochondrial morphology, or genetic perturbation. Nevertheless, the bridge remains experimentally immature: the reference study establishes the ALDOB–DRP1 mechanism in PH models, whereas growth-factor stimulation represents an adjacent assay variable. Direct experiments would be required to determine whether PDGF-BB changes ALDOB lactylation, SIRT1 abundance, DRP1 modification, or mitochondrial fission in the same model.

Limitations and Transferability

Several limitations should guide interpretation. First, hypoxic human PASMCs capture an important component of PH biology but do not represent every clinical PH subtype or all vascular and inflammatory cell populations. Rodent validation improves biological relevance, yet species differences may affect lactylation enzymes, mitochondrial regulation, and vascular responses.

Second, the study supports a multi-step pathway, but each step may have distinct kinetics and context dependence. ALDOB is a metabolic enzyme as well as a modified protein, so additional work is needed to separate effects on catalytic activity, protein interactions, subcellular localization, and broader glycolytic organization. Likewise, SENP3 and SIRT1 have functions beyond the specific ALDOB–DRP1 circuit; genetic or pharmacological manipulation may therefore produce pathway effects that are not entirely attributable to one substrate.

Third, the reported in vivo attenuation of PH progression is mechanistically informative but should not be equated with clinical efficacy. Pharmacological suppression of a modification may have delivery, selectivity, and toxicity challenges. The article is also presented as an article in press, so readers should consult the final version for any revised figures, methods, or interpretation. Overall, the most transferable conclusion is the framework linking lactate-associated protein modification to mitochondrial dynamics, not an immediate therapeutic prescription.

Research Support Resources

For controlled vascular-cell workflows, researchers can use PDGF-BB, murine recombinant protein (SKU P1048) as a defined mitogenic input when validated for the selected cells. Its PDGF-BB mitogen activity can support a cell proliferation assay with PDGF-BB and provide context for smooth muscle cell proliferation studies. Because PDGF-BB acts through PDGFR-α and PDGFR-β signaling, it may be useful as an assay comparator, but it should not be interpreted as part of the ALDOB K87 mechanism established by the reference study. The material is intended for research use only.